SNOA vs SSKN vs DERM vs SKIN vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, McKesson Corporation is actually cheaper at 16.

7x.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -99. 2% for Sonoma Pharmaceuticals, Inc. (SNOA). Over 10 years, the gap is even starker: MCK returned +339. 0% versus SNOA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), STRATA Skin Sciences, Inc.

(SSKN) is the lower-risk stock at -0. 38β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately -566% more volatile than SSKN relative to the S&P 500. On balance sheet safety, Sonoma Pharmaceuticals, Inc. (SNOA) carries a lower debt/equity ratio of 7% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: The Beauty Health Company grew EPS 55. 6% year-over-year, compared to -242. 9% for Journey Medical Corporation. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -30. 1% for STRATA Skin Sciences, Inc. — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MCK leads at 1. 5% versus -27. 6% for SSKN. At the gross margin level — before operating expenses — SKIN leads at 65. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, McKesson Corporation (MCK) trades at 16.

7x forward P/E versus 69. 9x for Journey Medical Corporation — 53. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 131. 8% to $11. 75.

In this comparison, MCK (0.

4% yield) pays a dividend. SNOA, SSKN, DERM, SKIN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, STRATA Skin Sciences, Inc.

(SSKN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 38)). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SSKN: -99. 6%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SNOA (Healthcare) and SSKN (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and MCK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.